Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Shareholder Meeting (November 2024)
25 slides from Cynata Therapeutics's shareholder meeting presentation, Nov 19, 2024
Slide 1: ASX Announcement: AGM Chair's address and presentation
ASX ANNOUNCEMENT 19 November 2024 Melbourne, Australia; 19 November 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to release a copy of the Chair’s address and Managing Director’s presen
Slide 2: Chair's Address to Shareholders
Chair’s Address to Shareholders 2024 Annual General Meeting It is my pleasure to address you all today and provide an overview of Cynata’s progress over the last year. Following my address, I will invite Kilian and his senior management team to provide an update on the Company’s activities and outlo
Slide 3: A Clinical Stage Company Pioneering the Next Generation of Cellular Therapies
For personal use only A Clinical Stage Company Pioneering the Next Generation of Cellular Therapies Managing Director’s Presentation Dr Kilian Kelly Annual General Meeting 19 November 2024
Slide 4: Important information
Important information Summary information This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries Forward-looking statements (CYP, or Cynata) which is current as at 15 November 2024. This Presentation should be read in This Presentation contains certain
Slide 5: Corporate overview
Corporate overview Share price1 Largest shareholders For personal use only 13.1% Bioscience Managers is an international healthcare investment firm headquarter in Melbourne that finances and enables innovative science and technology with the potential to transform healthcare. 10.0% Fidelity Internat
Slide 6: Target indications
Target indications Indication Trial phase Upcoming catalysts* Market opportunity For personal use only Acute Graft vs Host Disease (aGvHD) Phase 2 Enrolment completion – H1 2025 FDA Orphan Designation US$600m1 ongoing Results – H2 2025 Cynata Funded & Managed Phase 1 Diabetic Foot Ulcers (DFU) ongoi
Slide 7: FY 2024 | A year of progress
FY 2024 | A year of progress Multiple clinical trials advanced • Phase 3 osteoarthritis trial – patient enrolment completed For personal use only • Phase 2 aGvHD trial – first patient enrolled • Phase 1 DFU trial – patient enrolment completed • Phase 1/2 kidney transplant trial approved Further enco
Slide 8: Cynata's revolutionary Cymerus platform technology
For personal use only Cynata’s revolutionary Cymerus platform technology
Slide 9: Why MSCs?
Why MSCs? Mesenchymal Stem Cells For personal use only Key Unique Properties¹ 1 2 3 Tissue Repair & Anti-Inflammatory Immunomodulatory Regeneration Importance: Inflammation and inappropriate immune responses contribute to many diseases/medical disorders, and often lead to tissue damage. Consequently
Slide 10: Conventional MSC manufacturing process
Conventional MSC manufacturing process Isolation of Each donor Culture expansion of MSCs Many donors MSCs from Patients provides cells from each donation each donation Donor 1 Donor 2 For personal use only Donor 3 Donor 4 Standard Donor x Process¹ MSCs must be isolated New donors must be Extensive c
Slide 11: The problem
The problem Traditional manufacturing methods used to produce MSCs can encounter the following challenges: Consistency issues Inconsistent MSCs produce inconsistent & unreliable results For personal use only Potency issues Different potency levels in MSCs produce inconsistent & unreliable results Sc
Slide 12: The solution: the Cymerus process
The solution: the Cymerus process One iPSC Vial of iPSCs iPSC expansion Formation of Patients donor bank from bank and differentiation MSCs For personal use only One donor Cymerus Process iPSCs are culture Blood donation from a Cells from same iPSC expanded, then turned All batches of Cymerus single
Slide 13: Summary: advantages of Cymerus platform
Summary: advantages of Cymerus platform Traditional MSC Manufacturing Process For personal use only Traditional Cymerus MSCs Platform Conventional donor-derived MSCs are difficult to produce at scale, and since they are derived from different donors, Effectively limitless issues with potential incon
Slide 14: Ongoing clinical trials
For personal use only Ongoing clinical trials
Slide 15: aGvHD | Phase 2 clinical trial
aGvHD | Phase 2 clinical trial Indication High risk acute graft versus host disease (aGvHD)1 For personal use only Product CYP-001 (Cymerus iPSC-derived MSCs for intravenous infusion) • Randomised, double-blind, placebo-controlled trial Study Design • ~60 adults (steroids + CYP-001 vs steroids + pla
Slide 16: DFU | Phase 1 clinical trial
DFU | Phase 1 clinical trial Indication Non-healing diabetic foot ulcers (DFU) For personal use only CYP-006TK (Novel silicone dressing seeded with Cymerus iPSC-derived MSCs) Product • Randomised controlled trial in ~30 adults • Patients randomised to receive either standard of care or CYP-006TK for
Slide 17: OA | Phase 3 clinical trial
OA | Phase 3 clinical trial Indication Osteoarthritis (OA) of the knee (Kellgren-Lawrence Grade 2-3) For personal use only Product CYP-004 (Cymerus iPSC-derived MSCs for intra-articular injection) • Randomised, double-blind placebo-controlled trial in ~320 adults1 Study Design • Each participant rec
Slide 18: Kidney transplant | Phase 1/2 clinical trial
Kidney transplant | Phase 1/2 clinical trial Indication Prevention of kidney transplant rejection For personal use only Product CYP-001 (Cymerus iPSC-derived MSCs for intravenous infusion) • ~16 patients to receive CYP-001 after kidney transplantation: cohort 1 (n=3); cohort 2 (n=3); cohort 3 (n=10)
Slide 19: Outlook and commercial potential
For personal use only Outlook and commercial potential
Slide 20: Drivers of commercial partnering
Drivers of commercial partnering Lining up the ingredients for success • Compelling clinical efficacy and safety For personal use only • Ethical source • Simple administration • Scalable to large output • Broad portfolio of clinical and preclinical programs • Potential demonstrated in multiple disti
Slide 21: Industry connections
Industry connections • Upcoming catalysts will accelerate and broaden partnering discussions. • We attend leading conferences in our sector, to tell our story and open new discussions For personal use only • Following on from multiple events earlier this year, selected key events going forward inclu
Slide 22: JP Morgan BioWeek – key for partnering
JP Morgan BioWeek – key for partnering JP Morgan BioWeek*, held in San Francisco in the first half of January every year, is the world’s most significant biotech and pharma partnering and For personal use only investment event. Usually more than 10,000 pharma and biotech representatives and inve
Slide 23: Upcoming catalysts
Upcoming catalysts* Results of FOUR clinical trials expected between late 2024 and early 2026 Phase 2 For personal use only Enrolment Results aGvHD complete Phase 1 Results DFU Phase 3 Results osteo- Results arthritis Results Phase 1/2 First Results kidney patient (Cohort 1) transplant enrolled Star
Slide 24: Summary
Summary For personal use only Platform Compelling Billion dollar Technology Clinical Data markets Proven Multiple Commercial Indications Interest Manufacturing Excellent Safety Numerous Near- Challenges Profile Term Catalysts Overcome 22
Slide 25: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne Victoria 3121 Australia cynatatherapeutics info@cynata.com @cynatastemcells www.cynata.com cynata-therapeutics
Cynata Therapeutics — Shareholder Meeting (November 2024) on 6ix